Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedJan 20, 2026
DataAggregated Company Financials
Companies5
  • 7D-4.8%
  • 3M-0.8%
  • 1Y7.3%
  • YTD-1.2%

Over the last 7 days, the Biotech industry has gained 1.2%. During this same period, the Genmab underperformed, falling 5.5%. This means that the industry has gained 14% over the past year. In the next few years, earnings are forecast to decline by 5.8% annually.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 20 Jan 2026DKK 169.6bDKK 40.8bDKK 19.1b6.1x8.9x4.2x
Thu, 18 Dec 2025DKK 171.8bDKK 40.5bDKK 19.0b5.9x9.1x4.2x
Sat, 15 Nov 2025DKK 170.8bDKK 40.4bDKK 18.1b9.7x9.5x4.2x
Mon, 13 Oct 2025DKK 179.8bDKK 39.1bDKK 16.8b12.9x10.7x4.6x
Wed, 10 Sep 2025DKK 157.5bDKK 38.9bDKK 16.8b12.4x9.4x4.1x
Fri, 08 Aug 2025DKK 131.2bDKK 27.0bDKK 7.4b13.1x17.9x4.9x
Sun, 06 Jul 2025DKK 120.7bDKK 26.8bDKK 7.3b10.6x16.6x4.5x
Tue, 03 Jun 2025DKK 134.6bDKK 27.4bDKK 7.5b11.2x18x4.9x
Thu, 01 May 2025DKK 132.1bDKK 27.3bDKK 7.7b11.7x17.2x4.8x
Sat, 29 Mar 2025DKK 138.7bDKK 27.3bDKK 7.7b11.8x18.1x5.1x
Mon, 24 Feb 2025DKK 165.3bDKK 27.7bDKK 7.8b12.5x21.2x6x
Wed, 22 Jan 2025DKK 165.5bDKK 26.0bDKK 4.7b17.3x35.2x6.4x
Fri, 20 Dec 2024DKK 161.6bDKK 26.0bDKK 4.7b16.6x34.4x6.2x
Sun, 17 Nov 2024DKK 157.0bDKK 26.0bDKK 4.7b15.7x33.4x6x
Tue, 15 Oct 2024DKK 173.8bDKK 25.5bDKK 5.5b20.9x31.8x6.8x
Thu, 12 Sep 2024DKK 197.6bDKK 25.5bDKK 5.5b23.3x36.1x7.7x
Sat, 10 Aug 2024DKK 193.4bDKK 24.8bDKK 5.6b18.1x34.3x7.8x
Mon, 08 Jul 2024DKK 193.1bDKK 24.8bDKK 5.6b17.2x34.3x7.8x
Wed, 05 Jun 2024DKK 177.3bDKK 24.8bDKK 5.6b18.6x31.5x7.1x
Fri, 03 May 2024DKK 176.8bDKK 23.9bDKK 5.0b18.5x35.1x7.4x
Sun, 31 Mar 2024DKK 190.9bDKK 23.9bDKK 5.0b19.7x38x8x
Tue, 27 Feb 2024DKK 185.8bDKK 22.8bDKK 4.2b24.6x44.1x8.2x
Thu, 25 Jan 2024DKK 165.1bDKK 23.3bDKK 4.2b22.9x39.7x7.1x
Sat, 23 Dec 2023DKK 175.3bDKK 23.3bDKK 4.2b25.7x42.1x7.5x
Mon, 20 Nov 2023DKK 174.6bDKK 23.3bDKK 4.2b24.6x41.9x7.5x
Wed, 18 Oct 2023DKK 176.7bDKK 22.0bDKK 4.7b20.3x37.3x8x
Fri, 15 Sep 2023DKK 206.1bDKK 22.0bDKK 4.7b23.7x43.5x9.4x
Sun, 13 Aug 2023DKK 193.6bDKK 20.6bDKK 3.9b38.5x50x9.4x
Tue, 11 Jul 2023DKK 195.5bDKK 19.5bDKK 4.4b39.4x44.4x10x
Thu, 08 Jun 2023DKK 206.4bDKK 19.5bDKK 4.4b43x46.8x10.6x
Sat, 06 May 2023DKK 205.8bDKK 17.9bDKK 4.1b32.3x50.3x11.5x
Mon, 03 Apr 2023DKK 197.4bDKK 17.9bDKK 3.5b30.6x55.8x11x
Wed, 01 Mar 2023DKK 202.3bDKK 17.3bDKK 3.1b31.4x64.4x11.7x
Fri, 27 Jan 2023DKK 202.6bDKK 14.7bDKK 3.3b30.7x61.9x13.8x
Price to Earnings Ratio

61.9x


Total Market Cap: DKK 202.6bTotal Earnings: DKK 3.3bTotal Revenue: DKK 14.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 32.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 9.4x which is lower than its 3-year average PE of 32.9x.
  • The 3-year average PS ratio of 7.3x is higher than the industry's current PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 80% per year over the last three years.
  • Revenues for these companies have grown 40% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-0.74%
Healthcare-1.22%
Biotech-4.80%
Biotech-4.80%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
STRAP Strategic PartnersDKK 716.004.7%
+DKK 1.3m		-19.4%PB1.7x

Latest News

GMAB
DKK 2,043.00
Genmab
7D
-5.5%
1Y
35.3%

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
ZEAL
DKK 400.20
Zealand Pharma
7D
-2.5%
1Y
-42.6%

ZEAL: Metabolic Collaboration Will Support Future Upside Despite Trimmed Fair Value

Analysts have trimmed their price target on Zealand Pharma to approximately $746 from about $774, citing a slightly higher discount rate and revenue growth headwinds, partially offset by a modestly improved profit margin and a higher assumed future P/E multiple. What's in the News OTR Therapeutics and Zealand Pharma A/S entered into a multi program collaboration and license agreement to discover and develop therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
BAVA
DKK 192.55
Bavarian Nordic
7D
-3.0%
1Y
-1.1%

BAVA: HERA Procurement Contract And Mpox Demand Are Expected To Drive Upside

Analysts have kept their price target for Bavarian Nordic unchanged at €260. This reflects only small tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions rather than a shift in their overall view.
BIOPOR
DKK 1.03
BioPorto
7D
-4.5%
1Y
-31.6%
STRAP
DKK 716.00
Strategic Partners
7D
4.7%
1Y
-19.4%